Core Viewpoint - Vaccinex, Inc. has decided to delist its common stock from Nasdaq following a suspension of trading since December 18, 2024, due to a notice from the Nasdaq Hearings Panel [1][2] Company Overview - Vaccinex, Inc. is a clinical-stage biotechnology company focused on treating neurodegenerative diseases and cancer by inhibiting SEMA4D, which is believed to trigger damaging inflammation [1][4] - The company's lead product, pepinemab, is designed to block SEMA4D and is being evaluated for Alzheimer's disease and various cancers [4][7] Delisting Details - The company plans to file a Form 25 with the Securities and Exchange Commission around March 17, 2025, to officially remove its common stock from Nasdaq [2] - The decision to delist follows a notice from Nasdaq regarding the delisting of the company's securities [2] Product Development Focus - Vaccinex aims to continue the development of pepinemab through partnerships, grants, and other financing avenues [3] - Pepinemab has been studied in clinical trials for Alzheimer's disease and is also being evaluated in combination therapies for cancer, including studies with KEYTRUDA® and BAVENCIO® [4][5]